|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Graf D, Vallbohmer D, Knoefel WT, Kröpil
P, Antoch G, Sagir A and Häussinger D: Multimodal treatment of
hepatocellular carcinoma. Eur J Intern Med. 25:430–437. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Litvinov SV, Velders MP, Bakker HA,
Fleuren GJ and Warnaar SO: Ep-CAM: A human epithelial antigen is a
homophilic cell-cell adhesion molecule. J Cell Biol. 125:437–446.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baeuerle PA and Gires O: EpCAM (CD326)
finding its role in cancer. Br J Cancer. 96:417–423. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
van der Gun BT, Melchers LJ, Ruiters MH,
de Leij LF, McLaughlin PM and Rots MG: EpCAM in carcinogenesis: The
good, the bad or the ugly. Carcinogenesis. 31:1913–1921. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Went PT, Lugli A, Meier S, Bundi M,
Mirlacher M, Sauter G and Dirnhofer S: Frequent EpCam protein
expression in human carcinomas. Hum Pathol. 35:122–128. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schmidt M, Scheulen ME, Dittrich C, Obrist
P, Marschner N, Dirix L, Schmidt M, Ruttinger D, Schuler M,
Reinhardt C, et al: An open-label, randomized phase II study of
adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in
patients with metastatic breast cancer. Ann Oncol. 21:275–282.
2010. View Article : Google Scholar
|
|
8
|
Niedzwiecki D, Bertagnolli MM, Warren RS,
Compton CC, Kemeny NE, Benson AB, Eckhardt SG, Alberts S, Porjosh
GN, Kerr DJ, et al: Documenting the natural history of patients
with resected stage II adenocarcinoma of the colon after random
assignment to adjuvant treatment with edrecolomab or observation:
Results from CALGB 9581. J Clin Oncol. 29:3146–3152. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maetzel D, Denzel S, Mack B, Canis M, Went
P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M, et al: Nuclear
signalling by tumour-associated antigen EpCAM. Nat Cell Biol.
11:162–171. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ralhan R, Cao J, Lim T, Macmillan C,
Freeman JL and Walfish PG: EpCAM nuclear localization identifies
aggressive thyroid cancer and is a marker for poor prognosis. BMC
Cancer. 10:3312010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ralhan R, He HC, So AK, Tripathi SC, Kumar
M, Hasan MR, Kaur J, Kashat L, MacMillan C, Chauhan SS, et al:
Nuclear and cytoplasmic accumulation of Ep-ICD is frequently
detected in human epithelial cancers. PLoS One. 5:e141302010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jachin S, Bae JS, Sung JJ, Park HS, Jang
KY, Chung MJ, Kim DG and Moon WS: The role of nuclear EpICD in
extrahepatic cholangiocarcinoma: Association with β-catenin. Int J
Oncol. 45:691–698. 2014.PubMed/NCBI
|
|
13
|
Srivastava G, Assi J, Kashat L, Matta A,
Chang M, Walfish PG and Ralhan R: Nuclear Ep-ICD accumulation
predicts aggressive clinical course in early stage breast cancer
patients. BMC Cancer. 14:7262014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim DG, Park SY, Kim H, Chun YH, Moon WS
and Park SH: A comprehensive karyotypic analysis on a newly
established sarcomatoid hepatocellular carcinoma cell line SH-J1 by
comparative genomic hybridization and chromosome painting. Cancer
Genet Cytogenet. 132:120–124. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dollé L, Theise ND, Schmelzer E, Boulter
L, Gires O and van Grunsven LA: EpCAM and the biology of hepatic
stem/progenitor cells. Am J Physiol Gastrointest Liver Physiol.
308:G233–G250. 2015. View Article : Google Scholar :
|
|
16
|
Chan AW, Tong JH, Chan SL, Lai PB and To
KF: Expression of stemness markers (CD133 and EpCAM) in
prognostication of hepatocellular carcinoma. Histopathology.
64:935–950. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Winter MJ, Nagelkerken B, Mertens AE,
Rees-Bakker HA, Briaire-de Bruijn IH and Litvinov SV: Expression of
Ep-CAM shifts the state of cadherin-mediated adhesions from strong
to weak. Exp Cell Res. 285:50–58. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chaves-Pérez A, Mack B, Maetzel D,
Kremling H, Eggert C, Harréus U and Gires O: EpCAM regulates cell
cycle progression via control of cyclin D1 expression. Oncogene.
32:641–650. 2013. View Article : Google Scholar
|
|
19
|
Münz M, Kieu C, Mack B, Schmitt B, Zeidler
R and Gires O: The carcinoma-associated antigen EpCAM upregulates
c-myc and induces cell proliferation. Oncogene. 23:5748–5758. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Litvinov SV, Balzar M, Winter MJ, Bakker
HA, Bruijn IH, Prins F, Fleuren GJ and Warnaar SO: Epithelial cell
adhesion molecule (Ep-CAM) modulates cell-cell interactions
mediated by classic cadherins. J Cell Biol. 139:1337–1348. 1997.
View Article : Google Scholar
|
|
21
|
Lin CW, Liao MY, Lin WW, Wang YP, Lu TY
and Wu HC: Epithelial cell adhesion molecule regulates tumor
initiation and tumorigenesis via activating reprogramming factors
and epithelial-mesenchymal transition gene expression in colon
cancer. J Biol Chem. 287:39449–39459. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Philip R, Heiler S, Mu W, Buchler MW,
Zoller M and Thuma F: Claudin-7 promotes the epithelial-mesenchymal
transition in human colorectal cancer. Oncotarget. 6:2046–2063.
2015. View Article : Google Scholar
|
|
24
|
Medici D, Hay ED and Olsen BR: Snail and
Slug promote epithelial-mesenchymal transition through
beta-catenin-T-cell factor-4-dependent expression of transforming
growth factor-beta3. Mol Biol Cell. 19:4875–4887. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Garg M: Epithelial-mesenchymal transition
- activating transcription factors - multifunctional regulators in
cancer. World J Stem Cells. 5:188–195. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bokemeyer C: Catumaxomab - trifunctional
anti-EpCAM antibody used to treat malignant ascites. Expert Opin
Biol Ther. 10:1259–1269. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
MacDonald GC, Rasamoelisolo M, Entwistle
J, Cuthbert W, Kowalski M, Spearman MA and Glover N: A phase I
clinical study of intratumorally administered VB4-845, an
anti-epithelial cell adhesion molecule recombinant fusion protein,
in patients with squamous cell carcinoma of the head and neck. Med
Oncol. 26:257–264. 2009. View Article : Google Scholar
|
|
28
|
Kowalski M, Guindon J, Brazas L, Moore C,
Entwistle J, Cizeau J, Jewett MAS and MacDonald GC: A phase II
study of oportuzumab monatox: An immunotoxin therapy for patients
with noninvasive urothelial carcinoma in situ previously treated
with bacillus Calmette-Guerin. J Urol. 188:1712–1718. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ogawa K, Tanaka S, Matsumura S, Murakata
A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanabe M, et al:
EpCAM-targeted therapy for human hepatocellular carcinoma. Ann Surg
Oncol. 21:1314–1322. 2014. View Article : Google Scholar
|
